Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials
U. Costabel, Y. Inoue, L. Richeldi, H. R. Collard, S. Stowasser, I. Tschoepe, A. Azuma (Essen, Ingelheim am Rhein, Germany; Osaka, Tokyo, Japan; Southampton, United Kingdom; San Francisco, United States Of America; Reims, France)
Source: International Congress 2014 – Clinical trials in IPF
Session: Clinical trials in IPF
Session type: Oral Presentation
Number: 1907
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
U. Costabel, Y. Inoue, L. Richeldi, H. R. Collard, S. Stowasser, I. Tschoepe, A. Azuma (Essen, Ingelheim am Rhein, Germany; Osaka, Tokyo, Japan; Southampton, United Kingdom; San Francisco, United States Of America; Reims, France). Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials. Eur Respir J 2014; 44: Suppl. 58, 1907
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: